Skip to main content Skip to navigation
CD14 FITC
Product Details
Down Arrow Up Arrow


BD™
LPS receptor; LPS-R; Myeloid cell-specific leucine-rich glycoprotein
Human
Mouse BALB/c IgG2b, κ
Human Monocytes
Flow cytometry
25 μg/mL
20 μL
I M35; II M67; III M337; IV M301
929
Phosphate buffered saline with gelatin and 0.1% sodium azide.
CE_IVD


Preparation And Storage

The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.

Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

345784 Rev. 1
Antibody Details
Down Arrow Up Arrow
MφP9

CD14 is intended for in vitro diagnostic use in the identification of cells expressing CD14 antigen, using a BD FACS™ brand flow cytometer. The flow cytometer must be equipped to detect light scatter and the appropriate fluorescence, and be equipped with appropriate analysis software for data acquisition and analysis. Refer to your instrument user’s guide for instructions.

345784 Rev. 1
Format Details
Down Arrow Up Arrow
FITC
Fluorescein (FITC) is part of the BD blue family of dyes. This is a small organic fluorochrome with an excitation maximum (Ex Max) at 494-nm and an emission maximum (Em Max) at 518-nm. FITC is designed to be excited by the Blue laser (488-nm) and detected using an optical filter centered near 520 nm (e.g., a 530/30-nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
FITC
Blue 488 nm
494 nm
518 nm
345784 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "345784" on CiteAb

Development References (18)

  1. Bernard A, Boumsell L, Hill C. Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman S, ed. Leucocyte Typing. New York, NY: Springer-Verlag; 1984:82-108.
  2. Bernstein ID, Self S. Joint report of the Myeloid Section of the Second International Workshop on Human Leukocyte Differentiation Antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, ed. Leukocyte Typing II: Human Myeloid and Hematopoietic Cells. New York, NY: Springer-Verlag; 1986:1-25.
  3. Callea V, Marabito F, Oliva BM, et al. Surface CD14 positivity in B-cell chronic lymphocytic leukaemia is related to clinical outcome. Br J Haematol. 1999; 107:347-352. (Biology).
  4. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
  5. Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. H42-A2. 2007. (Biology).
  6. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Rothe G, Schmitz G. Leukemia. 1996; 10:877-895. (Biology).
  7. Dimitriu-Bona A, Burmester GR, Waters SJ, Winchester RJ. Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. J Immunol. 1983; 130(1):145-152. (Biology). View Reference
  8. Drexler HG, Thiel E, Ludwig WD. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia. 1991; 5:637-645. (Biology).
  9. Drexler HG. Classification of acute myeloid leukemias--a comparison of FAB and immunophenotyping.. Leukemia. 1987; 1(10):697-705. (Biology). View Reference
  10. Goyert SM, Ferrero E. Biochemical analysis of myeloid antigens and cDNA expression of gp55 (CD14). In: McMichael AJ. A.J. McMichael .. et al., ed. Leucocyte typing III : white cell differentiation antigens. Oxford New York: Oxford University Press; 1987:613-619.
  11. Hansen I, Meyer K, Hokland P. Flow cytometric identification of myeloid disorders by asynchronous expression of the CD14 and CD66 antigens. Eur J Haematol. 1998; 61:339-346. (Biology).
  12. Herrmann F, Komischke B, Odenwald E, Ludwig W. Use of monoclonal antibodies as a diagnostic tool in human leukemia, I: Acute myeloid leukemia and acute phase of chronic myeloid leukemia. Blut. 1983; 47:157-163. (Biology).
  13. Jackson AL, Warner NL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clincial Laboratory Immunology, Third Edition. Washington DC: American Society for Microbiology; 1986:226-235.
  14. Jayaram Y, Hogg N. Surface expression of CD14 molecules on human neutrophils. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:796-797.
  15. Khalidi HS, Medeiros LJ, Chang KL, Brynes RK, Slovak ML, Arber DA. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol. 1998; 109:211-220. (Biology).
  16. NCCLS document. 2001. (Biology).
  17. Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230. (Biology).
  18. Ziegler-Heithbrock HWL, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunol Today. 1993; 14:121-125. (Biology).
View All (18) View Less
345784 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For In Vitro Diagnostic Use.

 

23-22942-00

Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.